We are delighted to have been recognised as the “Heroes of British Export” at the Made in Britain Impact Awards 2025. This award celebrates the continued and combined efforts of Paxman’s International Team to make scalp cooling technology more widely accessible across the globe.
Part of this recognition acknowledges their commercial acumen and their capacity for forging relationships with healthcare providers and distributors, in addition to how they’ve leveraged this to flexibly establish business all over the world. Ultimately, this encourages more healthcare facilities in more countries to adopt scalp cooling and offer patients the chance to both retain their hair and protect their follicles for quicker regrowth.
Expanding Access Through Innovation and Localisation
Over the past year, Paxman has taken important steps to ensure that patients and healthcare professionals across the globe can use scalp cooling confidently and effectively. One key achievement has been the localisation of our software into multiple languages. This not only improves ease of use but also supports protocol adherence, helping patients achieve the best possible outcomes wherever they receive treatment.
The development of a global training platform will also play a major role in making scalp cooling more consistent across different healthcare settings. The system enables clinicians to access comprehensive education and best practice guidance, helping to ensure that the therapy is delivered safely and effectively.
Strengthening the Evidence for Scalp Cooling
Paxman continues to lead research in scalp cooling efficacy, working with clinical partners in over 17 countries. More than 65 studies and 8,000 patients have now contributed to a growing body of evidence demonstrating the benefits of this supportive therapy.
The recent publication of the Scalp Cooling Registry, which includes data from over 7,000 patients (with an estimated 98% of patients treated using Paxman devices), represents the world’s largest real-world dataset in this field. This evidence reinforces the effectiveness of scalp cooling and provides valuable insights that can help improve patient care globally. The Paxman team have deployed resources on The Scalp Cooling Registry over the past year to help both patients and clinicians understand the evidence of scalp cooling efficacy and offer estimations of hair retention based on the results.
Our research and funding also extend into new areas, including trials on challenging chemotherapy regimens such as anthracyclines and antibody-drug conjugates (ADCs). In addition, we are exploring how topical antioxidants may enhance the protective effects of scalp cooling in the near future.
Championing Equity and Representation in Cancer Care
We remain committed to ensuring that scalp cooling is effective and accessible for everyone. Our ongoing U.S. clinical trial involving patients of colour is helping to build an evidence base that better reflects the diversity of people affected by cancer. This work aims to support more equitable access to scalp cooling across all patient populations and treatment settings.
Building Global Recognition and Collaboration
Scalp cooling is increasingly being recognised as an important part of supportive cancer care. Paxman’s technology is now recommended in leading clinical guidelines in the U.K., U.S., Germany, the Netherlands, Japan, Australia, and France, with further discussions underway in other countries. Inclusion in these guidelines further reinforces the benefit of scalp cooling and encourages more healthcare providers to adopt the treatment.
Earlier in the year, Paxman also joined forces with Dignitana, merging two pioneers in the field to create the world’s first unified global leader in scalp cooling. This collaboration allows us to better share knowledge, support healthcare providers, and expand access for patients around the world.
Michael Garro Robles, Lucy Collingwood, Anna Parker, and Susan McAuley, accepting the award on behalf of Paxman.
We are both honoured and humbled by this award – a testament to the ongoing work of our International Team, who through their commercial excellence have contributed to the outstanding quarterly and year-on-year growth of Paxman via strategic international expansion, flexible business models, in-market partnerships, and new innovations and initiatives. This award only fuels us even further to seek out and strengthen partnerships, push for further international expansion, and ultimately ensure that scalp cooling becomes a standard of cancer care for patients anywhere in the world.
